Meet a Researcher: Dr Rachel Taylor
Dr Rachel Taylor is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team at the University of Manchester.
Search
Search results
Drugs for cancer and alcoholism show promise for RP
With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise.
Meet our volunteers: Martin Hills
Martin started volunteering for Retina UK in 2014 after retiring as a Chartered Civil Engineer.
Optogenetics
The BBC covered a story on Monday 24 May about optogenetics partially restoring the sight of a man living with retinitis pigmentosa in France.
Medical research
Retina UK has invested more than £16million into cutting-edge research since the charity was founded in 1976.
Webinar: Inflammation and retinal degeneration in RP
Inflammation and retinal degeneration in retinitis pigmentosa: Can lessons learned in the lab help us identify treatments in the clinic?
New stem cell treatment gains approval to enter US clinical trials
New stem cell treatment gains approval to enter US clinical trials
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Disappointing news from ProQR clinical trial for LCA10
ProQR has published the top-line results from its Phase 2/3 “Illuminate” trial of the RNA therapy sepofarsen for Leber congenital amaurosis type 10 caused by a specific mutation in the CEP290 gene.
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP